Business context and reporting period
Filing identity differs from request metadata: the supplied 10-K is for Owens & Minor, Inc. (NYSE: OMI), not Accendra Health Inc. It reports the year ended December 31, 2012, with unaudited quarterly data for Q4 2012.
Owens & Minor distributes medical and surgical supplies and provides supply-chain and third-party logistics services. In August 2012, it acquired European logistics provider Movianto for approximately $157 million and began reporting Domestic and International segments.
Financial results and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Net revenue | $8.908 billion | $8.628 billion |
| Gross margin | $924.7 million; 10.38% of revenue | $857.5 million; 9.94% |
| Operating earnings (GAAP) | $196.8 million; 2.21% | $203.5 million; 2.36% |
| Adjusted operating earnings (non-GAAP) | $206.9 million; 2.32% | $216.7 million; 2.51% |
| Net income | $109.0 million | $115.2 million |
| Diluted EPS | $1.72 | $1.81 |
| Cash from operating activities | $218.5 million | $68.4 million |
| Cash and cash equivalents at year-end | $97.9 million | $135.9 million |
| Total debt at year-end | $217.6 million | $214.6 million |
Revenue increased 3.2%, while net income declined 5.4% and adjusted diluted EPS fell from $1.94 to $1.85. Gross margin improved largely due to Movianto and fee-for-service growth; SG&A rose to $682.6 million from $610.7 million, reflecting the acquisition and higher expenses. Adjusted results exclude acquisition-related and exit/realignment charges; the company reported $10.2 million of such charges in 2012.
Q4 2012 revenue was $2.325 billion versus $2.196 billion in Q4 2011; gross margin was $270.8 million versus $214.0 million, and net income was $24.9 million versus $23.9 million. Movianto contributed 5.5% of consolidated Q4 revenue, its first full quarter in the company’s results.
Operating cash flow improved substantially, helped by lower Domestic inventory and improved Domestic days sales outstanding. Investing cash use was $190.9 million, primarily reflecting the Movianto acquisition; financing cash use was $68.4 million, including $55.7 million of dividends and $15.0 million of share repurchases. The company had $345 million available under its $350 million revolving facility, with no borrowings and $5 million of letters of credit outstanding. It also had $200 million of 6.35% senior notes due in 2016. The reported debt-to-equity ratio was 0.22.
Material changes, outlook, risks and unusual items
- Domestic revenue grew modestly, but net new customer activity reduced revenue by $24.6 million; management cited lower healthcare utilization, reduced product-price inflation, lower government purchasing and supplier rationalization.
- International segment revenue was $176.7 million for the four months after acquisition, and the segment reported an operating loss of $5.4 million. Acquisition integration and transition costs remain relevant.
- Management announced a 9% increase in the quarterly dividend to $0.24 per share in February 2013. It anticipated continuing quarterly dividends, subject to Board discretion. No specific revenue or earnings guidance was provided.
- The company targeted approximately $4 million of additional 2013 lease-exit and related charges. A multi-year, $50 million U.S. information-technology transformation was initiated in 2012.
- Customer and channel concentration is significant: approximately 80% of consolidated revenue came from hospitals affiliated with four major GPOs; the top ten U.S. customers represented about 23% of consolidated revenue. The MedAssets/Broadlane agreement was due to expire in August 2013; new Novation and Premier agreements were in place.
- Other key risks include intense pricing competition, supplier concentration (the ten largest domestic suppliers accounted for about 55% of revenue), healthcare policy and reimbursement changes, customer credit exposure, fuel costs, foreign currency and regulatory risks, and reliance on information systems and third-party IT services.
- California litigation and compensation-related expenses of $2.0 million were partly offset by a $1.1 million class-action settlement. The filing states pending legal matters were not expected to have a material adverse effect. A potential California tax-incentive payment of up to $7 million was contingent and not assured.
- Management and the auditor concluded internal control over financial reporting was effective for the assessed scope, but Movianto was excluded from the 2012 assessment because of the acquisition timing; it was to be included in the 2013 assessment. The financial statement audit opinion was unqualified.
Important facts for investors to verify
- Confirm the intended issuer: the filing supplied is Owens & Minor, not Accendra Health.
- Review the full filing’s financial statements and notes for Movianto’s purchase accounting, segment results, integration costs and subsequent performance.
- Track renewal, retention and economics of major GPO and supplier relationships, particularly the then-expiring MedAssets/Broadlane contract.
- Assess whether operating cash flow remains strong after the 2012 working-capital release, and monitor inventory, receivables and liquidity.
- Verify execution and cost benefits of the IT transformation and planned 2013 exit/realignment actions; monitor whether acquisition-related charges recur.
- Consider customer and supplier concentration, contingent legal and tax matters, and the exclusion of Movianto from the 2012 internal-control assessment.